Acarix AB (7AC) AI Stock Analysis

Acarix AB

(Frankfurt:7AC)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue growthTTM revenue growth of 14.5% shows the company is expanding sales, although from a small base. If sustained, broader adoption can improve operating leverage and help spread fixed costs across more revenue, supporting a path toward stronger earnings as commercialization scales.

Negative Factors

Deep operating lossesExtremely negative net and EBIT margins show that the current revenue base remains far below the cost structure. Although losses have narrowed versus prior years, the scale of the deficit indicates that sustained growth and substantial cost discipline are still required before breakeven.

Acarix AB (7AC) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 20.36M
Dividend Yield: ―
Average Volume (3M): 12.07K
Price to Earnings (P/E): -5.3
Beta (1Y): 1.08
Revenue Growth: 71.66%
EPS Growth: 39.22%
Country: Germany
Employees: 8
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Acarix AB Business Overview & Revenue Model

Company Description

Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADSc...

Acarix AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:7AC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:SECT.B	74Outperform	SEK 67.51B	101.10	30.26%	0.38%	13.94%	5.70%
SE:MNTC	58Neutral	SEK 435.95M	-91.65	-3.61%	―	15.87%	92.43%
SE:SEZI	57Neutral	SEK 532.17M	-5.30	-35.44%	―	18.56%	28.11%
SE:BACTI.B	53Neutral	SEK 560.70M	87.78	1.93%	―	-0.51%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:HEART	44Neutral	SEK 142.76M	-2.33	-54.68%	―	―	―

* Healthcare Sector Average

Performance Comparison

DE:7AC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:7AC	Acarix AB	0.02	0.01	41.18%
SE:SEZI	Senzime AB	3.29	-2.33	-41.55%
SE:BACTI.B	Bactiguard Holding AB	15.80	-0.40	-2.47%
SE:SECT.B	Sectra AB Class B	330.60	36.35	12.35%
SE:HEART	Scandinavian Real Heart AB	16.50	1.60	10.77%
SE:MNTC	Mentice AB	15.70	6.30	67.02%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Acarix AB AI Stock Analysis